These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 27040279)

  • 1. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
    Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
    Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
    Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study.
    Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S;
    Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term complete response after treatment with cytarabine, vincristine, and prednisone in an infant with refractory multisystem Langerhans cell histiocytosis.
    Cook R; Berkow RL; Kelly DR; Friedman GK
    Pediatr Blood Cancer; 2011 Jul; 57(1):180-1. PubMed ID: 21412968
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Outcome Comparison of Pediatric Langerhans Cell Histiocytosis Treated with Modified DAL-HX83/90 or JLSG-96 Protocol].
    Huang JB; Jiang L; Chen C; Xue HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1190-5. PubMed ID: 27531798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution.
    Egeler RM; de Kraker J; Voûte PA
    Med Pediatr Oncol; 1993; 21(4):265-70. PubMed ID: 8469221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
    Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
    Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
    [No Abstract]   [Full Text] [Related]  

  • 13. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
    Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
    Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
    Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
    BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies.
    Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27454. PubMed ID: 30207064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan.
    Imamura T; Sato T; Shiota Y; Kanegane H; Kudo K; Nakagawa S; Nakadate H; Tauchi H; Kamizono J; Morimoto A
    Int J Hematol; 2010 May; 91(4):646-51. PubMed ID: 20361277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapses of multisystem/multifocal bone Langerhans cell histiocytosis in paediatric patients: Data analysis from the JLSG-96/02 study.
    Sakamoto K; Morimoto A; Shioda Y; Imamura T; Imashuku S;
    Br J Haematol; 2023 Mar; 200(6):769-775. PubMed ID: 36511451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience.
    Derenzini E; Stefoni V; Pellegrini C; Gandolfi L; Broccoli A; Casadei B; Quirini F; Argnani L; Tonialini L; Zinzani PL
    BMC Cancer; 2015 Nov; 15():879. PubMed ID: 26552668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Langerhans-cell histiocytosis (histiocytosis X); 20-year experience in the Emma Kinderziekenhuis, 1969-1988].
    Egeler RM; de Kraker J; Voûte PA
    Ned Tijdschr Geneeskd; 1993 May; 137(19):955-60. PubMed ID: 8497330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.